Neurosense Therapeutics Ltd
NRSNW0.390USD
-0.310-43.06%
Market hours （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Neurosense Therapeutics Ltd Company
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Company Info
Ticker SymbolNRSNW
Company nameNeurosense Therapeutics Ltd
IPO dateDec 09, 2021
CEOMr. Alon Ben-Noon
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address11 Hamenofim St.
CityHERZLIYA
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code4672562
Phone97299531142
Websitehttps://www.neurosense-tx.com/
Ticker SymbolNRSNW
IPO dateDec 09, 2021
CEOMr. Alon Ben-Noon
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Feb 23
Updated: Sun, Feb 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
6
78.60K
0.00%
-114.75K
2025Q1
6
78.60K
0.00%
-114.75K
2024Q4
6
106.40K
0.00%
-91.99K
2024Q3
6
111.43K
0.00%
-96.87K
2024Q2
7
281.35K
0.00%
-114.32K
2024Q1
7
395.47K
0.00%
+21.94K
2023Q4
7
369.53K
0.00%
-28.20K
2023Q3
7
397.72K
0.00%
-24.43K
2023Q2
7
422.15K
0.00%
-55.70K
2023Q1
6
477.05K
0.00%
+29.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Clear Street LLC
65.76K
0%
+100.00
+0.15%
Mar 31, 2025
Citadel Advisors LLC
--
0%
-22.71K
-100.00%
Mar 31, 2025
Warberg Asset Management LLC
10.00K
0%
-7.94K
-44.25%
Mar 31, 2025
UBS Financial Services, Inc.
2.84K
0%
+2.75K
+2922.34%
Mar 31, 2025
Hudson Bay Capital Management LP
--
0%
-86.75K
-100.00%
Jun 30, 2024
BofA Global Research (US)
--
0%
-200.00
-100.00%
Dec 31, 2023
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
